Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Tyra Biosciences, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/16/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/17/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/17/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/17/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/22/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/22/2023 |
8-K
| Quarterly results|
Docs:
|
"Tyra Biosciences, Inc. Balance Sheet Data December 31, 2022 2021 Balance Sheet Data: Cash and cash equivalents $ 251,213 $ 302,182 Working capital 251,587 300,441 Total assets 266,181 306,701 Accumulated deficit Total stockholders’ equity 257,829 301,737 Tyra Biosciences, Inc. Statements of Operations and Comprehensive Loss Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development $ 10,400 $ 7,250 $ 43,008 $ 20,636 General and administrative 4,618 2,682 15,919 5,652 Total operating expenses 15,018 9,932 58,927 26,288 Loss from operations Other income : Interest income 2,156 5 3,652 13 Other income Total other income 2,123 2 3,602 Net loss and comprehensive loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weight..." |
|
| 03/01/2023 |
8-K
| Quarterly results |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 9.2% stake in TYRA BIOSCIENCES INC |
| 11/29/2022 |
8-K
| Other Events Interactive Data |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/03/2022 |
8-K
| Quarterly results |
| 10/14/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 10/03/2022 |
8-K
| Quarterly results |
| 10/03/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/04/2022 |
8-K
| Quarterly results|
Docs:
|
"Tyra Biosciences, Inc. Balance Sheet Data June 30, December 31, 2022 2021 Balance Sheet Data: Cash and cash equivalents $ 275,107 $ 302,182 Working capital 271,844 300,441 Total assets 287,118 306,701 Accumulated deficit Total stockholders’ equity 278,853 301,737 Tyra Biosciences, Inc. Statements of Operations and Comprehensive Loss Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Operating expenses: Research and development $ 12,047 $ 4,381 $ 21,692 $ 7,902 General and administrative 3,381 1,127 8,570 1,816 Total operating expenses 15,428 5,508 30,262 9,718 Loss from operations Other income : Interest income 346 4 364 5 Other expense Total other income 333 341 Net loss and comprehensive loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted-aver..." |
|
| 06/15/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/14/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/05/2022 |
8-K
| Quarterly results |
| 04/28/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/24/2022 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 5.9% stake in Tyra Biosciences, Inc. |
| 03/03/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/03/2022 |
8-K
| Quarterly results |
| 02/09/2022 |
SC 13G
| FMR LLC reports a 8.4% stake in TYRA BIOSCIENCES INC |
| 02/08/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 11/03/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
|
|
|